<DOC>
	<DOCNO>NCT00860158</DOCNO>
	<brief_summary>This trial investigate activity dasatinib plus LHRH analogue therapy high-risk localized prostate cancer .</brief_summary>
	<brief_title>Neoadjuvant Dasatinib Plus LHRH Analogue Therapy High-Risk Localized Prostate Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Dasatinib -100 mg administer daily per oral route 28 consecutive day . - Leuprolide acetate - 7.5 mg administer subcutaneously day 1 every 28 day ( + 7 day ) . The 28 day dasatinib leuprolide injection ( plus time require recover toxicity encounter ) define cycle . Patients treat maximum 3 cycle dasatinib leuprolide acetate . Radical Prostatectomy perform sooner 8 hour preferably within 24 hour last administered dasatinib dose . All attempt make patient surgery 8 hour within 24 hour last dose dasatinib . If surgery delay imperative , dasatinib therapy continue least 24 hour plan surgery . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Hematopoietic : - Hemoglobin ( Hgb ) ≥ 8.0 g/dL - Platelets ≥ 100 K/mm3 - Absolute neutrophil count ( ANC ) ≥ 1.0 K/mm3 Hepatic : - Total bilirubin &lt; 2.0 X Upper Limit Normal ( ULN ) - Aspartate aminotransferase ( AST ) &lt; 2.5 X ULN - Alanine aminotransferase ( ALT ) &lt; 2.5 X ULN Renal : - Calculated creatinine clearance ≥ 60 cc/min use Cockcroft-Gault formula Cardiovascular : - No uncontrolled angina , congestive heart failure myocardial infarction within 6 month prior registration protocol therapy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate . Clinical stage T1T3a disease . Must willing tumor biopsy , previous tumor tissue unavailable tumor marker analysis . Kattan preoperative nomogrampredicted ( base stage , Prostate Specific Antigen ( PSA ) Gleason score ) 5year risk recurrencefree survival 80 % less Must deem eligible radical prostatectomy . Must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 6 week treatment discontinuation . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . No evidence regional , lymph node distant metastasis clinical radiological assessment . All baseline radiology study must perform within 28 day prior registration protocol therapy . No prior malignancy past 2 year except basal cell squamous cell carcinoma skin . Other cancer low potential metastasis , situ cancer ( e.g. , Grade 1 , TA TCC ( low grade superficial bladder cancer ) , colonic polyp focus adenocarcinoma ) enrol approval Sponsor Investigator . No prior hormonal therapy exception oral 5alphareductase inhibitor ( finasteride , dutasteride , etc. ) . Patients receive prior oral antiandrogen therapy ( bicalutamide , flutamide , nilutamide , etc . ) , prior LHRH agonist therapy ( leuprolide , goserelin acetate , etc . ) , prior orchiectomy ineligible . No prior systemic chemotherapy radiotherapy prostate cancer allow . Transurethral resection prostate benign prostatic hypertrophy ( BPH ) oral alphablockers ( terazosin , tamsulosin , doxazosin ) permit . No history hemorrhage thrombotic event ( cerebrovascular accident , deep vein thrombosis , pulmonary embolism , etc . ) within 6 month prior registration protocol therapy . No history diagnose congenital bleeding disorder ( e.g. , von Willebrand 's disease ) No history diagnose acquire bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) registration protocol therapy . No history ongoing recent ( ≤ 3 month registration protocol therapy ) significant gastrointestinal bleeding No ongoing anticoagulation and/or antiplatelet therapy allow . No unresolved pleural pericardial effusion grade within 3 month registration protocol therapy . No uncontrolled angina , congestive heart failure MI within 6 month prior registration protocol therapy . No diagnosed congenital long QT syndrome . No history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de Pointes ) . No prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Following medication must discontinue least 7 day prior registration protocol therapy withhold duration dasatinib therapy : Drugs generally accept risk cause Torsades de Pointes Patient must receive prohibit CYP3A4 inhibitor /inducers/ substrate Anticoagulation and/or antiplatelet therapy avoid potential bleeding risk . No major surgical procedure , open biopsy , significant trauma within 28 day prior registration protocol therapy . Ability comply study and/or followup procedure requirement . No treatment investigational agent medical condition within 28 day prior registration protocol therapy . No clinically significant infection condition , investigator 's opinion , deem patient unsuitable candidate receive study drug . Ability take oral medication ( dasatinib must swallow whole ) . No known history hypokalemia correct prior registration protocol therapy . No known history hypomagnesemia correct prior registration protocol therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>